{"id":"W4411333831","doi":"10.1002/hon.70093_50","title":"50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"Science and Engineering Research Board; BeiGene; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Gilead Sciences; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Mantle cell lymphoma; Internal medicine; Lymphoma; Oncology; Materials science; Composite material","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001161256,0.0006863532,0.0009861009,0.0002440156,0.0002877026,0.0007002752,0.0005347056,0.0005662005,0.003663664],"category_scores_gemma":[0.000637433,0.0003716071,0.0005577916,0.0002804635,0.0004866055,0.000456718,0.0002488211,0.001922493,0.001045467],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005147925,"about_ca_system_score_gemma":0.000783123,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00080877,"about_ca_topic_score_gemma":0.001981528,"domain_scores_codex":[0.9996428,0.0001406639,0.00002732079,0.00006506139,0.00004907126,0.00007501114],"domain_scores_gemma":[0.9995408,0.00007461124,0.00007248839,0.00005978533,0.00002871868,0.000223703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5966091,0.08777475,0.01568024,0.0006084495,0.001152925,0.0002949866,0.0002445775,0.00185725,0.1108649,0.0001879975,0.008225952,0.1764988],"study_design_scores_gemma":[0.2479444,0.6826084,0.04748056,0.00004381218,0.0005831799,0.0004995724,0.00005476768,0.001461615,0.01373976,0.0001281588,0.005427425,0.0000284356],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952677,0.0009278042,0.0004516539,0.0001735819,0.00005850123,0.0006702899,0.0009322237,0.0001145667,0.001403682],"genre_scores_gemma":[0.9948533,0.000473517,0.0006471503,0.0002616002,0.00008868801,0.00046077,0.00173883,0.00002264618,0.00145344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003663664,"threshold_uncertainty_score":0.01225615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02473748507732553,"score_gpt":0.3116219902016331,"score_spread":0.2868845051243075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}